We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-14.95%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.72B
AUM Growth
-$950M
Cap. Flow
-$368M
Cap. Flow %
-21.39%
Top 10 Hldgs %
48.56%
Holding
373
New
67
Increased
88
Reduced
111
Closed
78

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$59.4M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$32.9M
3
AMGN icon
Amgen
AMGN
+$18M
4
LLY icon
Eli Lilly
LLY
+$15.9M
5
BMY icon
Bristol-Myers Squibb
BMY
+$7.23M

Top Sells

Rank Stock Value
1
SHPG
Shire pic
SHPG
+$6.04M
2
ABT icon
Abbott
ABT
+$4.77M
3
RGNX icon
Regenxbio
RGNX
+$4.1M
4
CELG
Celgene Corp
CELG
+$3.94M
5
UTHR icon
United Therapeutics
UTHR
+$3.59M

Sector Composition

Rank Sector Weight
1 Healthcare 17.88%
2 Financials 0.23%
3 Consumer Staples 0.05%
4 Technology 0.03%
5 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
226
PUT
Rocket Pharmaceuticals
RCKT
$343M
$305K 0.02%
125
– –
FOLD
227
DELISTED
Amicus Therapeutics
FOLD
$300K 0.02%
+60,309
New +$417K
ADXS
228
PUT
DELISTED
Advaxis Inc
ADXS
$296K 0.02%
+28
New +$3.78K
DRNA
229
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$288K 0.02%
100,000
+50,000
+100% +$178K
PHIO icon
230
Phio Pharmaceuticals
PHIO
$11.7M
$284K 0.02%
+7
New +$547K
TMBR
231
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
$265K 0.02%
47
+3
+7% +$15.3K
DVAX
232
DELISTED
Dynavax Technologies
DVAX
$261K 0.02%
66,091
-455,784
-87% -$3.34M
ROSG
233
DELISTED
Rosetta Genomics Ltd.
ROSG
$248K 0.01%
+49,278
New +$377K
FLXN
234
CALL
DELISTED
Flexion Therapeutics, Inc.
FLXN
$240K 0.01%
+126
New +$2.41K
PTLA
235
PUT
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$240K 0.01%
+107
New +$2.09K
CSCI
236
PUT
DELISTED
COSCIENS Biopharma Inc. Common Stock
CSCI
$221K 0.01%
6
-1
-14% -$373
NUROW
237
DELISTED
NeuroMetrix, Inc. Warrants
NUROW
$211K 0.01%
37,722
-540
-1% -$3.89K
FLXN
238
DELISTED
Flexion Therapeutics, Inc.
FLXN
$208K 0.01%
10,914
-1,262
-10% -$24.1K
PRQR icon
239
ProQR Therapeutics
PRQR
$248M
$196K 0.01%
40,000
-18,910
-32% -$97.4K
JUNO
240
CALL
DELISTED
Juno Therapeutics, Inc.
JUNO
$194K 0.01%
103
– –
ARCT icon
241
Arcturus Therapeutics
ARCT
$163M
$193K 0.01%
13,123
+10,686
+438% +$160K
SGMO
242
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$193K 0.01%
63,204
+30,400
+93% +$111K
ADXS
243
CALL
DELISTED
Advaxis Inc
ADXS
$193K 0.01%
+18
New +$2.43K
IMUC.WS
244
DELISTED
ImmunoCellular Therapeutics Ltd.
IMUC.WS
$192K 0.01%
+383,471
New +$130K
HRTX icon
245
CALL
Heron Therapeutics
HRTX
$92M
$185K 0.01%
+141
New +$2.21K
IMMU
246
DELISTED
Immunomedics Inc
IMMU
$184K 0.01%
50,000
-247,310
-83% -$732K
SYBX
247
DELISTED
Synlogic
SYBX
$180K 0.01%
+954
New +$154K
QNRX
248
Quoin Pharmaceuticals
QNRX
$8.44M
$177K 0.01%
1
– –
LXRX icon
249
PUT
Lexicon Pharmaceuticals
LXRX
$1.04B
$167K 0.01%
121
-479
-80% -$7.68K
RNVA
250
DELISTED
Rennova Health, Inc.
RNVA
$167K 0.01%
4,494
-1,561
-26% -$88.7K
8 9
10
11 12

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2016 Portfolio in Review

As of Q4 2016, Sabby Management held 373 positions worth $1.72B, down 36% from $2.67B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sabby Management withdrew a net $368M in Q4 2016, closing 78 positions and reducing 111 holdings. Its most notable exit was Shire pic, an estimated $6.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 9.2% a quarter earlier, followed by Financials and Consumer Staples.

Against the trend, Sabby Management opened a new position in Eli Lilly worth $15.7M.

  • Sabby Management's largest Q4 2016 buy was Eli Lilly: 213,113 shares worth $15.7M.
  • Sabby Management added most to Sarepta Therapeutics in Q4 2016, an estimated $59.4M increase.
  • Sabby Management's biggest Q4 2016 reduction was Regenxbio, cutting an estimated $4.1M.
  • Sabby Management fully exited Shire pic in Q4 2016, selling an estimated $6.04M.
  • Sabby Management's ten largest holdings make up 49% of its $1.72B portfolio in Q4 2016.
  • Sabby Management opened 67 new positions and closed 78 in Q4 2016.
  • Sabby Management's portfolio value fell 36% quarter-over-quarter to $1.72B.

Based on Sabby Management's 13F filing for Q4 2016, filed 14 Feb 2017.